Repligen (RGEN) Q2 Earnings Meet Estimates

Core Viewpoint - Repligen reported quarterly earnings of $0.33 per share, matching the Zacks Consensus Estimate, but down from $0.53 per share a year ago [1]. Financial Performance - The company posted revenues of $154.07 million for the quarter ended June 2024, missing the Zacks Consensus Estimate by 0.16%, and down from $159.17 million year-over-year [2]. - Over the last four quarters, Repligen has surpassed consensus EPS estimates only once and topped consensus revenue estimates two times [2]. Stock Performance - Repligen shares have declined approximately 23.3% since the beginning of the year, contrasting with the S&P 500's gain of 14.5% [4]. - The current Zacks Rank for Repligen is 4 (Sell), indicating expected underperformance in the near future [7]. Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.38 on revenues of $161.78 million, and for the current fiscal year, it is $1.46 on revenues of $637.24 million [8]. - The trend for estimate revisions ahead of the earnings release was unfavorable, which may impact future stock movements [6][7]. Industry Context - The Medical - Biomedical and Genetics industry, to which Repligen belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable industry outlook [9].